← Back to Infinity Pharmaceuticals Stock
Infinity Pharmaceuticals (INFIQ) News
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (OTC: INFIQ) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the important October 16, 2023 lead plaintiff deadline. SO WHAT: If you purchased Infinity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen.
LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
LOS ANGELES, CA / ACCESSWIRE / October 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI). Such investors are advised to contact Robert S.
LOS ANGELES, CA / ACCESSWIRE / October 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.
NEW YORK , Oct. 5, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the "Class Period"), of the important October 16, 2023 lead plaintiff deadline. SO WHAT: If you purchased Infinity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2022 and July 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 16, 2023.